Trelagliptin
Trelagliptin is a long-acting, once-weekly oral dipeptidyl peptidase-4 (DPP-4) inhibitor that maintains sustained GLP-1 and GIP levels throughout the week by preventing incretin hormone degradation, enhancing glucose-dependent insulin secretion and suppressing glucagon to improve glycemic control in type 2 diabetes. Its prolonged pharmacodynamic effect from a single weekly dose distinguishes it from daily DPP-4 inhibitors and may improve patient adherence. It is approved in Japan for type 2 diabetes management.
Peso Molecular
357,4000 g/mol
LogP
0,70
TPSA
93,70 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Estrutura 2D
Cite this structure
Embed this structure
SMILES
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O
InChI
InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1
Molecular Formula
C18H20FN5O2
HBD / HBA
1 / 6
Ligações Rotacionáveis
3
Átomos Pesados
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Trelagliptin is a long-acting, once-weekly oral dipeptidyl peptidase-4 (DPP-4) inhibitor that maintains sustained GLP-1 and GIP levels throughout the week by preventing incretin hormone degradation, enhancing glucose-dependent insulin secretion and suppressing glucagon to improve glycemic control in type 2 diabetes. Its prolonged pharmacodynamic effect from a single weekly dose distinguishes it from daily DPP-4 inhibitors and may improve patient adherence. It is approved in Japan for type 2 diabetes management.
Yes, Trelagliptin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1650443. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 15983988. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trelagliptin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trelagliptin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trelagliptin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trelagliptin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trelagliptin"></drugfyi-drug>